All In Biotech

Drug Trial Radar · NCT05523947

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Aug 26, 2022

Primary completion

Mar 31, 2028

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Yuhan CorporationIndustry
Sponsor type
Industry
First posted
Sep 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.

Conditions

  • HER2-Positive Solid Tumor

Interventions

  • YH32367Drug

    Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8. Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll approximately 75 and 40 patients, respectively.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) up to Day 21Time frame: in dose escalation part, an average of 21 days
  2. Objective Response Rate (ORR)Time frame: through dose expansion part completion, approximately 2.5 year

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Withdrawn

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Southern Oncology Clinical Research Unit

    Adelaide, Australia · Terminated

  • Austin Health

    Melbourne, Australia · Withdrawn

  • Breast Cancer Research Centre - WA

    Perth, Australia · Withdrawn

  • Blacktown Hospital

    Sydney, Australia · Recruiting

  • Gachon Gil University Medical Center

    Incheon, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, St. Mary's hospital

    Seoul, South Korea · Recruiting

  • Ulsan University Hospital

    Ulsan, South Korea · Recruiting

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Catholic University of Korea St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Gyeongsang National University Hospital

    Jinju, Gyeongsangnam-do, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.